EMCURENSEEmcure Pharmaceuticals LimitedHighNeutral
Announced Wed, 1 Apr · 21:46 IST

Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition

Listed Co AcquisitionStrategic Transactions View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.6%1-day move
₹1590.00
prior close
₹1585.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.4-3.4-3.3-4.3-2.6-2.1-1.6+0.9+0.2+3.2+2.6+13.1+6.9+16.9
Up moveDown movePending
AI summary

Emcure Pharmaceuticals' step-down subsidiary Mantra Pharma Inc. acquired 100% of Cutimed Inc., a Canadian company engaged in cosmetics and dermatological products, for CAD $ 5.05 million in cash. Cutimed had annual turnover of CAD $ 2.8 million (FY2025) and has been operating since 2011. Immediately after the acquisition on April 1, 2026, Cutimed was amalgamated with Mantra Pharma Inc. through a short-form procedure under Canadian law. The transaction was not a related party transaction and is aligned with Emcure's core business strategy to strengthen its Canadian dermatological and cosmetic portfolio. No change in Emcure's shareholding pattern will occur.

Likely market impact

Positive signal for shareholders as the acquisition consolidates Emcure's Canadian operations and expands its dermatology and cosmetics product portfolio. The deal is not expected to materially impact financials given Cutimed's small size relative to Mantra (CAD $ 81 million turnover).